An academic proteomics and genomics core director at a top East Coast research institute discusses the use of proteomics across multiple disease areas including oncology and neurological disorders. This stakeholder believes that the technologies today are not yet under their definition of ‘next gen proteomics’ which involves novel protein sequencing rather than hypothesis driven antibody or aptamer methods. This stakeholder is highly familiar with Olink, SomaLogic, Quanterix, Luminex, and MSD, and also closely follows the developments with tools they consider ‘next-generation’ including Nautilus, Encodia, Erisyon, and QuantumSi. They oversee tens of thousands of proteomics experiments annually, and comment that throughput, assay reproducibility, and dynamic range are key selection criteria for proteomics assays. As a core director with instrument purchasing authority, this stakeholder has great insights into how emerging technologies will need to perform to be seen as successful and which applications will benefit most.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.